Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYTPET: PET-Adapted Therapy in DLBCL
NCT00324467Phase 2Unknown
- Sponsor
- BC Cancer
- Start
- Aug 2006
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by BC Cancer. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
ifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00324467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00324467.